Document:

Loan Agreement October 7, 2021

   
 LOAN AGREEMENT
 October 7, 2021
  
 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$15,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on October 7, 2021. As per request of the Borrower, the Lender transferred the Principal Sum into the account of Cell MedX Corp., the Borrower’s parent corporation with an address at 123 W. Nye Ln, Suite 446, Carson City, NV 89706.
  
 The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from October 7, 2021 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
  
 The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
  
 	 LENDER
	 BORROWER

	 Richard N. Jeffs
	 Cell MedX (Canada) Corp.

	  
	  

	 Per:
	 Per:

	  
	  

	  
	  

	 /s/ Richard N. Jeffs
	 /s/  Yanika Silina

	 Richard N. Jeffs
	 Yanika Silina, Director

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
 
  
 PROMISSORY NOTE
  
 	 Principal Amount: USD$15,000
	 October 7, 2021

  
  
 FOR VALUE RECEIVED Cell MedX (Canada) Corp., (the “Borrower”) promises to pay on demand to the order of Richard N. Jeffs (the “Lender”) the sum of $15,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from October 7, 2021 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
  
 For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
  
 The Borrower acknowledges that, at the Borrower’s request, the Lender transferred the Principal Sum to Cell MedX Corp., the Borrower’s parent corporation.
  
 The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
  
 The Borrower waives presentment, protest, notice of protest and notice of dishonor of this promissory note.
  
  
 BORROWER
 Cell MedX (Canada) Corp.
  
 Per:
  
  
 /s/ Yanika Silina
 Yanika Silina, DirectorLoan Agreement October 26, 2021

   
 LOAN AGREEMENT
 October 26, 2021
  
 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$35,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on October 26, 2021. As per request of the Borrower, the Lender transferred the Principal Sum into the account of Cell MedX Corp., the Borrower’s parent corporation with an address at 123 W. Nye Ln, Suite 446, Carson City, NV 89706.
  
 The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from October 26, 2021 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
  
 The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
  
 	 LENDER
	 BORROWER

	 Richard N. Jeffs
	 Cell MedX (Canada) Corp.

	  
	  

	 Per:
	 Per:

	  
	  

	  
	  

	 /s/ Richard N. Jeffs
	 /s/  Yanika Silina

	 Richard N. Jeffs
	 Yanika Silina, Director

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
 
  
 PROMISSORY NOTE
  
 	 Principal Amount: USD$35,000
	 October 26, 2021

  
  
 FOR VALUE RECEIVED Cell MedX (Canada) Corp., (the “Borrower”) promises to pay on demand to the order of Richard N. Jeffs (the “Lender”) the sum of $35,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from October 26, 2021 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
  
 For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
  
 The Borrower acknowledges that, at the Borrower’s request, the Lender transferred the Principal Sum to Cell MedX Corp., the Borrower’s parent corporation.
  
 The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
  
 The Borrower waives presentment, protest, notice of protest and notice of dishonor of this promissory note.
  
  
 BORROWER
 Cell MedX (Canada) Corp.
  
 Per:
  
  
 /s/ Yanika Silina
 Yanika Silina, DirectorLoan Agreement November 24, 2021

   
 LOAN AGREEMENT
 November 24, 2021
  
 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$35,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on November 24, 2021.
  
 The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from November 24, 2021 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
  
 The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
  
 	 LENDER
	 BORROWER

	 Richard N. Jeffs
	 Cell MedX (Canada) Corp.

	  
	  

	 Per:
	 Per:

	  
	  

	  
	  

	 /s/ Richard N. Jeffs
	 /s/  Yanika Silina

	 Richard N. Jeffs
	 Yanika Silina, Director

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
 PROMISSORY NOTE
  
 	 Principal Amount: USD$35,000
	 November 24, 2021

  
  
 FOR VALUE RECEIVED Cell MedX (Canada) Corp., (the “Borrower”) promises to pay on demand to the order of Richard N. Jeffs (the “Lender”) the sum of $35,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from November 24, 2021 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
  
 For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
  
 The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
  
 The Borrower waives presentment, protest, notice of protest and notice of dishonor of this promissory note.
  
  
 BORROWER
 Cell MedX (Canada) Corp.
  
 Per:
  
  
 /s/ Yanika Silina
 Yanika Silina, DirectorLoan Agreement November 29, 2021

   
 LOAN AGREEMENT
 November 29, 2021
  
 Brad Hargreaves (the “Lender”) of 904-1616 Bayshore Drive, Vancouver, BC V6G 3L1. advanced CDN$7,500 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on November 29, 2021.
  
 The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from November 29, 2021 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
  
 The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
  
 	 LENDER
	 BORROWER

	 Brad Hargreaves
	 Cell MedX Corp.

	  
	  

	 Per:
	 Per:

	  
	  

	  
	  

	 /s/ Brad Hargreaves
	 /s/  Yanika Silina

	 Brad Hargreaves
	 Yanika Silina, Director

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
 PROMISSORY NOTE
  
 	 Principal Amount: CDN$7,500
	 November 29, 2021

  
  
 FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Brad Hargreaves (the “Lender”) the sum of $7,500 lawful money of Canada (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from November 29, 2021 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
  
 For the purposes of this promissory note, Interest Rate means six (6) per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
  
 The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
  
 The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.
  
  
 BORROWER
 Cell MedX Corp.
  
 Per:
  
  
 /s/ Yanika Silina
 Yanika Silina, Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]